Bone Biologics Files 8-K Report

Ticker: BBLGW · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1419554

Bone Biologics Corp 8-K Filing Summary
FieldDetail
CompanyBone Biologics Corp (BBLGW)
Form Type8-K
Filed DateMar 1, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, routine-filing

Related Tickers: BBLG

TL;DR

Bone Biologics filed a routine 8-K, no major news.

AI Summary

On March 1, 2024, Bone Biologics Corporation filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or significant corporate actions beyond routine reporting requirements.

Why It Matters

This filing indicates routine corporate activity and disclosure by Bone Biologics Corporation, but lacks specific material events or financial updates.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without any disclosed material events, financial changes, or significant corporate actions.

Key Players & Entities

  • Bone Biologics Corporation (company) — Registrant
  • March 1, 2024 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily for reporting "Other Events" and "Financial Statements and Exhibits" as of March 1, 2024.

Does this filing announce any new material events or agreements?

The provided text of the filing does not specify any new material events, agreements, or significant corporate actions.

What is the state of incorporation for Bone Biologics Corporation?

Bone Biologics Corporation is incorporated in Delaware.

What is the IRS number for Bone Biologics Corporation?

The IRS number for Bone Biologics Corporation is 42-1743430.

What is the business address of Bone Biologics Corporation?

The business address of Bone Biologics Corporation is 2 BURLINGTON WOODS DRIVE, SUITE 100, BURLINGTON, MA 01803.

Filing Stats: 423 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-03-01 08:05:30

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: March 1, 2024 By: / s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.